Former CEO and CFO join non-executive board and announce Richard Adams and Lauren Patterson to key executive positions
Wokingham, United Kingdom — March 31 2020 — With the goal of securing further growth across pharmaceutical, medical devices and clinical trials markets, the board of PRISYM ID has made changes to its senior leadership team. Life sciences and technology veteran Richard Adams has joined as CEO from Wilmington plc and Lauren Patterson, most recently CFO at Revium Group, has been appointed CFO.
PRISYM ID are a leading provider of data-led label and artwork management solutions designed for regulatory compliance used across pharmaceutical, medical device and clinical trial organizations. The company also confirms that former CEO Mick Daw and former CFO Barry Cooper will remain on the company’s board, and that their long experience will continue to be utilized in a non-executive capacity.
Richard Adams has been a leader in the healthcare and technology sector for the last 30 years, with a track record of leveraging innovation to deliver valuable solutions for customers. In previous roles as Divisional Director Healthcare at Wilmington plc and as Chief Executive Officer at Doctors.net.uk, Richard led the organizations' strategic direction, including international growth and a program of acquisitions to better serve customer needs.
Lauren Patterson is a qualified chartered accountant who has built considerable experience working with a number of quoted and private-owned organizations. As well as holding several positions within divisions of Revium Group, most latterly as CFO, Lauren was also Commercial Finance Director for Rentokil Initial and Group Finance Director of HR Wallingford.
Commenting on his appointment, Richard Adams said: “PRISYM ID is the only organization of its kind globally and it was clear to me that its regulatory information management technology can define the critical path in a life science supply chain. Getting it right is critical for patient safety, regulatory compliance and the success of clinical trials – while safeguarding brand reputation and trust.
“Acknowledging the fantastic work of Mick and Barry, this award-winning company has great further potential for growth, and I look forward to working with them and the company’s highly talented team.”